BR112012026147A2 - espiroderivados azacíclicos como inibidores de hsl - Google Patents

espiroderivados azacíclicos como inibidores de hsl

Info

Publication number
BR112012026147A2
BR112012026147A2 BR112012026147A BR112012026147A BR112012026147A2 BR 112012026147 A2 BR112012026147 A2 BR 112012026147A2 BR 112012026147 A BR112012026147 A BR 112012026147A BR 112012026147 A BR112012026147 A BR 112012026147A BR 112012026147 A2 BR112012026147 A2 BR 112012026147A2
Authority
BR
Brazil
Prior art keywords
azacyclic
spiroderivatives
hsl inhibitors
hsl
inhibitors
Prior art date
Application number
BR112012026147A
Other languages
English (en)
Inventor
Aurelia Conte
Daniel Hunziker
Jean Ackermann
Matthias Nettekoven
Stanley Wertheimer
Tanja Schulz-Gasch
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012026147A2 publication Critical patent/BR112012026147A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

esoiroderivados azacíclicos como inibidores de hsl. a invenção proporciona compostos que são dotados da fórmula geral (i) em que r~ 1~, r~ 2~, e a são tais como descritos neste contexto, composições que incluem os compostos e compostos para o tratamento de diabetes, síndromes metabólicas e obesidade (inibidores de hsl).
BR112012026147A 2010-04-15 2011-04-12 espiroderivados azacíclicos como inibidores de hsl BR112012026147A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160030 2010-04-15
PCT/EP2011/055670 WO2011128316A1 (en) 2010-04-15 2011-04-12 Azacyclic spiroderivatives as hsl inhibitors

Publications (1)

Publication Number Publication Date
BR112012026147A2 true BR112012026147A2 (pt) 2016-06-28

Family

ID=44010146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012026147A BR112012026147A2 (pt) 2010-04-15 2011-04-12 espiroderivados azacíclicos como inibidores de hsl

Country Status (14)

Country Link
US (1) US8097634B2 (pt)
EP (1) EP2558464B1 (pt)
JP (1) JP5956423B2 (pt)
KR (1) KR20130098153A (pt)
CN (1) CN102844316B (pt)
AR (1) AR080894A1 (pt)
BR (1) BR112012026147A2 (pt)
CA (1) CA2795101A1 (pt)
ES (1) ES2490266T3 (pt)
HK (1) HK1176607A1 (pt)
MX (1) MX2012010826A (pt)
RU (1) RU2567395C2 (pt)
TW (1) TW201202237A (pt)
WO (1) WO2011128316A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US9505728B2 (en) 2012-03-09 2016-11-29 Inception 2, Inc. Triazolone compounds and uses thereof
EP2935228B9 (en) 2012-12-20 2017-12-06 Inception 2, Inc. Triazolone compounds and uses thereof
SG11201601066VA (en) 2013-09-06 2016-03-30 Inception 2 Inc Triazolone compounds and uses thereof
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20190501A1 (es) * 2016-08-01 2019-04-10 Aptinyx Inc Moduladores nmda espiro-lactam y metodos de uso de los mismos
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
EP3490993B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1461339B1 (en) * 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
RU2007128987A (ru) * 2005-02-15 2009-03-27 Ново Нордиск А/С (DK) 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры
CN101115741A (zh) * 2005-02-15 2008-01-30 诺和诺德公司 3,4-二氢-1h-异喹啉-2-羧酸5-氨基吡啶-2-基酯
CN101336243A (zh) * 2005-12-05 2008-12-31 因塞特公司 内酰胺化合物和其使用方法
BRPI0619446A2 (pt) 2005-12-05 2011-10-04 Incyte Corp compostos de lactama, suas composições e método de modulação da atividade de 11bhsd1
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8440710B2 (en) * 2009-10-15 2013-05-14 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US8389539B2 (en) * 2009-12-01 2013-03-05 Hoffman-La Roche Inc. Azacyclic derivatives
RU2603263C2 (ru) * 2010-07-13 2016-11-27 Ф. Хоффманн-Ля Рош Аг Новые азациклические соединения
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds

Also Published As

Publication number Publication date
TW201202237A (en) 2012-01-16
EP2558464B1 (en) 2014-06-18
JP2013523859A (ja) 2013-06-17
US20110257212A1 (en) 2011-10-20
RU2567395C2 (ru) 2015-11-10
AR080894A1 (es) 2012-05-16
CA2795101A1 (en) 2011-10-20
CN102844316B (zh) 2015-02-25
EP2558464A1 (en) 2013-02-20
JP5956423B2 (ja) 2016-07-27
ES2490266T3 (es) 2014-09-03
WO2011128316A1 (en) 2011-10-20
KR20130098153A (ko) 2013-09-04
US8097634B2 (en) 2012-01-17
RU2012146875A (ru) 2014-05-20
MX2012010826A (es) 2012-10-10
HK1176607A1 (en) 2013-08-02
CN102844316A (zh) 2012-12-26

Similar Documents

Publication Publication Date Title
BR112012026147A2 (pt) espiroderivados azacíclicos como inibidores de hsl
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
MY153915A (en) Organic compounds
MX2011005934A (es) Compuestos organicos.
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
MA32508B1 (fr) Composes organiques
UA107791C2 (en) Pesticidal compositions
EA201071032A1 (ru) Гетероциклическое соединение
MA32937B1 (fr) Composes organiques
ECSP11011184A (es) Compuestos orgánicos
BR112014015905A2 (pt) composição
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BR112014015908A2 (pt) composição
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
EA201270590A1 (ru) Ингибиторы акт
MA32505B1 (fr) 5-alcynyl-pyrimidines
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
MA33948B1 (fr) Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques.
BR112012006176A2 (pt) inibidores macrocíclicos de jak
BR112012009496A2 (pt) composição farmacêutica, e, método para tratar diabetes tipo 2
TN2009000536A1 (en) Novel herbicides
BR112012017393A2 (pt) derivados de 2,5,7-oxazolpirimidina substituída
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
GEP20135998B (en) Heterocyclic sulfonamide derivatives

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05/02/2019.